280 Importantly, the HELIOS-B trial included patients diagnosed at earlier stages of ATTR-CM with milder clinical manifestations, 264 reflecting a shift toward earlier intervention in ATTR-CM management
Zhang Z, Xie Y, Yi Q et al (2025) PEAK1 maintains tight junctions in intestinal epithelial cells and resists colitis by inhibiting autophagy-mediated ZO-1 degradation
Pharmacol Res Perspect (2022) 10(5):e00998
922 In AKT-hyperactivated cancer cells, AKT directly phosphorylates the Ser343 site of TRPML1, inhibits the K552 ubiquitination degradation of TRPML1, and promotes the binding of TRPML1 to ARL8B, leading to lysosomal exocytosis
In theory, exogenous administration should carry minimal risk if the peptide faithfully replicates the native protein's action
We believe the strong pricing power of weight-loss drug Mounjaro supported a major part of the pricing gains